Search
Ginger
go.drugbank.com/drugs/DB10344ApprovedInvestigationalGinger allergenic extract is used in allergenic testing.
Mixtures: C Ottways Lax TabGTI-2501
go.drugbank.com/drugs/DB05406ExperimentalThe drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer. … GTI-2501 is a novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I clinical trial.
Transcrocetinate
go.drugbank.com/drugs/DB05974InvestigationalVitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.
Categories: Compounds used in a research, industrial, or household settingPalopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA. … Palopegteriparatide is a prodrug consisting of PTH(1-34) conjugated to a methoxy polyethylene glycol carrier (mPEG) via a proprietary TransCon Linker.
Synonyms: oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isole, Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34Bethanidine
go.drugbank.com/drugs/DB00217ApprovedA guanidinium antihypertensive agent that acts by blocking adrenergic transmission.
Moschus berezovskii musk sac resin
go.drugbank.com/drugs/DB14247InvestigationalMoschus berezovskii musk sac resin is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: Ma Ying Long HemorrhoidalPhentolamine
go.drugbank.com/drugs/DB00692ApprovedInvestigationalPhentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. … While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral
Ramoplanin
go.drugbank.com/drugs/DB04952ExperimentalRamoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.
CYT-6091
go.drugbank.com/drugs/DB05991ExperimentalIt was under investagtion in clinical trials NCT00356980 and NCT00436410 for the treatment of various cancers.
Categories: Compounds used in a research, industrial, or household setting